1 min read
Add as a preferred source on GoogleVir Biotechnology Shares Rise Nearly 10% in Premarket After Gilead Deal
Gilead will use Vir’s PRO-XTEN platform to discover and develop cancer drugs under an agreement valued at up to nearly $1.9 billion.
Vir Biotechnology shares traded nearly 10% higher in premarket trading on Oct. 14 after the company announced a licensing agreement with Gilead to use its PRO-XTEN platform for cancer drug discovery and development.
The agreement is valued at up to nearly $1.9 billion. Gilead will use Vir’s masking technology platform to discover and develop cancer drugs.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.